Abstract Aims Enzyme replacement therapy (ERT) for mucopolysaccharidosis II (MPS II) requires long‐term, weekly intravenous infusions often lasting over 3 h each time, which can burden paediatric patients and caregivers and negatively affect their quality of life and treatment compliance.
Kimitoshi Nakamura +6 more
wiley +1 more source
Compliance with current VTE prophylaxis guidelines and associated factors among admitted medical inpatients in Mehal Meda General Hospital, North Shewa Zone, Ethiopia: a cross-sectional study. [PDF]
Yitbarek T +3 more
europepmc +1 more source
Background By age three, 5%–75% of children have a documented antibiotic allergy (AL). Despite this prevalence, recognition remains low because of limited clinician knowledge and time. Our study evaluates a novel approach to identifying AL using electronic medical record (EMR) prescription patterns.
Georgia Koutsaplis +5 more
wiley +1 more source
Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study. [PDF]
Ye J, Huang K.
europepmc +1 more source
Oseltamivir drug‐disease modelling in infants with influenza virus infection
Abstract Aims Oseltamivir is a commonly used neuraminidase inhibitor for treatment of influenza infection, but little data exist regarding concentration‐response relationships. Methods Pharmacokinetic (PK) and viral dynamic data from an earlier NIAID Collaborative Antiviral Study Group trial in paediatric patients with influenza from 0–23 months of age
Kun Wang +4 more
wiley +1 more source
Venous thromboembolism prophylaxis in total shoulder arthroplasty: a matched cohort analysis. [PDF]
Katakam A +6 more
europepmc +1 more source
Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem +5 more
wiley +1 more source
Risk Factors for Subtherapeutic Exposure and Hepatotoxicity Threshold of Posaconazole: A Real-World Study in Chinese Patients with Invasive Pulmonary Fungal Infection. [PDF]
Wang B +5 more
europepmc +1 more source
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan +24 more
wiley +1 more source
Stakeholders Want a Menu of Choices: Findings from a Consultation Workshop on Improving Access to Secondary Prophylaxis of Rheumatic Fever and Rheumatic Heart Disease. [PDF]
Hla TK +6 more
europepmc +1 more source

